RESULT_COUNT: 193,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
HCM,HCM:UW,BBG00B6VCH45,Edison Issues Update on Hutchison China MediTech (HCM),2017-10-18 15:56:00 +0000,https://finance.yahoo.com/news/edison-issues-hutchison-china-meditech-155600328.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / October 18, 2017 / Data presented at the World Conference on Lung Cancer (WCLC) on combination approaches to treat resistant EGFR-driven non-small cell lung cancer (NSCLC) highlight ..."
HCM,HCM:UW,BBG00B6VCH45,Chi-Med and AstraZeneca’s Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET-Amplification,2017-10-17 06:00:00 +0000,https://finance.yahoo.com/news/chi-med-astrazeneca-savolitinib-shows-060000097.html?.tsrc=rss,Hutchison China MediTech Limited and AstraZeneca PLC today presented preliminary safety and clinical activity data of savolitinib when given in combination with either Tagrisso® or Iressa® in two Phase Ib/II proof-of-concept trials conducted in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with MET-amplification who had progressed following first-line treatment ...
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer,2017-10-16 06:00:00 +0000,https://finance.yahoo.com/news/chi-med-reports-preliminary-phase-060000305.html?.tsrc=rss,"Hutchison China MediTech Limited today reported preliminary clinical activity, safety, and tolerability data of fruquintinib, an investigational selective inhibitor of vascular endothelial growth factor receptor given in combination with Iressa®."
HCM,HCM:UW,BBG00B6VCH45,Hutchison China MediTech: Appointment of Director,2017-10-12 06:52:00 +0000,https://finance.yahoo.com/news/hutchison-china-meditech-appointment-director-065200089.html?.tsrc=rss,"Hutchison China MediTech Limited today announces that Professor Mok, Shu Kam Tony has been appointed as Independent Non-Executive Director and member of the Technical Committee with effect from October 12, 2017."
HCM,HCM:UW,BBG00B6VCH45,Asian ADRs Move Lower in Wednesday Trading,2017-10-04 14:49:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xYcqRtgQxxI/asian-adrs-move-lower-in-wednesday-trading-cm855136,American depositary receipts of Asian stocks were trading 0 17 lower at 171 93 on the Bank of New York Mellon Asia ADR Index on Wednesday American depositary receipts of Asian stocks were trading 0 17 lower at 171 93 on the Bank of New York Mellon Asia ADR Index on Wednesday In North Asia
HCM,HCM:UW,BBG00B6VCH45,What You Must Know About Hutchison China MediTech Limited’s (AIM:HCM) Return on Equity,2017-10-01 15:12:13 +0000,https://finance.yahoo.com/news/must-know-hutchison-china-meditech-151213220.html?.tsrc=rss,"Hutchison China MediTech Limited (AIM:HCM) generated a below-average return on equity of 7.52% in the past 12 months, while its industry returned 9.01%. HCM’s results could indicate a relatively inefficientRead More..."
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Highlights Oral Presentations at CSCO Annual Meeting,2017-09-29 07:03:00 +0000,https://finance.yahoo.com/news/chi-med-highlights-oral-presentations-070300497.html?.tsrc=rss,"Hutchison China MediTech Limited announced that new clinical data on three of its novel tyrosine kinase inhibitors, fruquintinib, savolitinib and theliatinib, were presented at the 20th Annual Meeting of the Chinese Society of Clinical Oncology , held in Xiamen, China, from September 26 to 30, 2017."
HCM,HCM:UW,BBG00B6VCH45,Chi-Med to Present Savolitinib and Fruquintinib Clinical Data at WCLC 2017 Annual Meeting,2017-09-29 06:58:00 +0000,https://finance.yahoo.com/news/chi-med-present-savolitinib-fruquintinib-065800834.html?.tsrc=rss,"Hutchison China MediTech Limited today announces that non-small cell lung cancer proof-of-concept clinical data on two of its novel tyrosine kinase inhibitors , savolitinib and fruquintinib, will be presented at the 18th World Conference on Lung Cancer , to be held in Yokohama, Japan from October 15 to 18, 2017."
HCM,HCM:UW,BBG00B6VCH45,Asian ADRs Move Lower in Wednesday Trading,2017-09-13 14:55:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pvLwCRA5F5M/asian-adrs-move-lower-in-wednesday-trading-cm845077,American depositary receipts of Asian stocks were trading 0 13 lower at 171 30 on the Bank of New York Mellon Asia ADR Index on Wednesday American depositary receipts of Asian stocks were trading 0 13 lower at 171 30 on the Bank of New York Mellon Asia ADR Index on Wednesday In North Asia
HCM,HCM:UW,BBG00B6VCH45,Validea Motley Fool Strategy Daily Upgrade Report - 9/12/2017,2017-09-12 12:35:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v-oj-iowMbE/validea-motley-fool-strategy-daily-upgrade-report-9122017-cm844140,The following are today s upgrades for Validea s Small Cap Growth Investor model based on the published strategy of Motley Fool This strategy looks for small cap growth stocks with solid fundamentals and strong price performance The following are today s upgrades for Validea s Small Cap
HCM,HCM:UW,BBG00B6VCH45,Is It Too Late To Buy Hutchison China MediTech Limited (AIM:HCM)?,2017-09-11 12:51:09 +0000,https://finance.yahoo.com/news/too-buy-hutchison-china-meditech-125109161.html?.tsrc=rss,"Hutchison China MediTech Limited (AIM:HCM), a pharmaceuticals, biotechnology and life sciences company based in Hong Kong, See our latest analysis for HCM What is HCM worth? HCM appears to beRead More..."
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Initiates a Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL-689 in Lymphoma Patients in China,2017-08-29 06:08:00 +0000,https://finance.yahoo.com/news/chi-med-initiates-phase-clinical-060800764.html?.tsrc=rss,"Hutchison China MediTech Limited has initiated a Phase I clinical trial of HMPL-689 in China. HMPL-689 is a novel, highly selective and potent small molecule inhibitor targeting phosphoinositide-3 kinase delta isoform , a key component in the B-cell receptor signaling pathway."
HCM,HCM:UW,BBG00B6VCH45,4 Key Takeaways From Paycom Software's CEO,2017-08-26 20:37:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FSxjAgaHkxA/4-key-takeaways-from-paycom-softwares-ceo-cm837583,Paycom Software NYSE PAYC can seemingly do no wrong having recently reported the latest in a string of impressive quarterly results With its history of outperformance you d think the company s edge would be fairly easy to define but that isn t quite the case In fact I
HCM,HCM:UW,BBG00B6VCH45,Validea Motley Fool Strategy Daily Upgrade Report - 8/22/2017,2017-08-22 08:37:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lW3LN2ODI_A/validea-motley-fool-strategy-daily-upgrade-report-8222017-cm835073,The following are today s upgrades for Validea s Small Cap Growth Investor model based on the published strategy of Motley Fool This strategy looks for small cap growth stocks with solid fundamentals and strong price performance The following are today s upgrades for Validea s Small Cap
HCM,HCM:UW,BBG00B6VCH45,Sunny Optical Surges to All-Time High on Strong Earnings Beat,2017-08-15 06:34:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Oeyr361QiNg/sunny-optical-surges-to-all-time-high-on-strong-earnings-beat-cm831986,Shares in Sunny Optical 2382 HK have surged to an all time high in Hong Kong trading on Tuesday after China s largest manufacturer of smartphone camera lenses posted a strong earnings beat Shares inSunny OpticalSunny Optical 2382 HK have surged to an all time high in Hong Kong
HCM,HCM:UW,BBG00B6VCH45,Paycom Software Delivers Another Home Run Earnings Report,2017-08-09 02:34:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/foI5vBoFR_s/paycom-software-delivers-another-home-run-earnings-report-cm829150,Paycom Software NYSE PAYC reported its second quarter earnings on August 2 In what s become a recurring theme for the provider of cloud based human capital management HCM software the company not only beat lofty analyst expectations but raised its forward guidance as well
HCM,HCM:UW,BBG00B6VCH45,Validea Warren Buffett Strategy Daily Upgrade Report - 8/8/2017,2017-08-08 08:34:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wP_eB3zED2E/validea-warren-buffett-strategy-daily-upgrade-report-882017-cm828480,The following are today s upgrades for Validea s Patient Investor model based on the published strategy of Warren Buffett This strategy seeks out firms with long term predictable profitability and low debt that trade at reasonable valuations The following are today s upgrades for Validea
HCM,HCM:UW,BBG00B6VCH45,Validea Motley Fool Strategy Daily Upgrade Report - 8/8/2017,2017-08-08 08:34:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EqgiUzouohw/validea-motley-fool-strategy-daily-upgrade-report-882017-cm828478,The following are today s upgrades for Validea s Small Cap Growth Investor model based on the published strategy of Motley Fool This strategy looks for small cap growth stocks with solid fundamentals and strong price performance The following are today s upgrades for Validea s Small Cap
HCM,HCM:UW,BBG00B6VCH45,"Hutchison China MediTech Ltd. :HCM-US: Earnings Analysis: For the six months ended June 30, 2017 : August 7, 2017",2017-08-07 18:35:24 +0000,http://finance.yahoo.com/r/8db399ed-7416-35e0-a27b-31d51ebed126/hutchison-china-meditech-ltd-hcm-us-earnings-analysis-for-the-six-months-ended-june-30-2017-august-7-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Hutchison China MediTech Ltd. reports financial results for the half-year ended June 30, 2017. We analyze the earnings along side the following peers of Hutchison China MediTech Ltd. – OncoMed Pharmaceuticals, Inc. and OrganiGram Holdings Inc (OMED-US and OGRMF-US) that have also reported for this period. Highlights Summary numbers: Revenues of ... Read more
<b>(Read more...)</b>"
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Reports 2017 Interim Results and Updates Shareholders on Key Clinical Programs,2017-07-31 06:00:00 +0000,https://finance.yahoo.com/news/chi-med-reports-2017-interim-060000470.html?.tsrc=rss,"Hutchison China MediTech Limited , the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the global market, today announces its unaudited financial results for the six months ended June 30, 2017."
HCM,HCM:UW,BBG00B6VCH45,What I'll Be Watching When Paycom Software Reports Earnings,2017-07-30 23:54:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H-o2fVCB8WI/what-ill-be-watching-when-paycom-software-reports-earnings-cm823951,Paycom Software s NYSE PAYC shareholders have enjoyed a heck of a ride recently The company s stock is up more than 50 year to date as demand for the company s cloud based human capital management HCM software remains strong And with shares currently trading at
HCM,HCM:UW,BBG00B6VCH45,[$$] 3 Chinese Stocks With Strong Earnings Growth,2017-07-18 00:49:00 +0000,http://finance.yahoo.com/r/0633f0e3-9dc3-3aef-a236-b9a2d80e606a/3-chinese-stocks-with-strong-earnings-growth-1500338955?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Alibaba dominates the headlines when it comes to fast growing Chinese companies, but there are plenty of lesser known stocks with strong earnings growth and red-hot share prices to boot.  Baozun offers an alternative way to play China’s red-hot e-commerce market."
HCM,HCM:UW,BBG00B6VCH45,Paycom Software's $1 Billion Ambitions,2017-07-12 00:44:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vChj5_rCOkM/paycom-softwares-1-billion-ambitions-cm814790,At investor conference appearances in May and June Paycom Software NYSE PAYC CEO Chad Richison spoke about why the company s all in one approach to human capital management HCM and payroll software continues to be so successful While providing color on the pace of new
HCM,HCM:UW,BBG00B6VCH45,3 Biggest Risks Facing Workday Inc.,2017-07-10 22:44:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Pj-O8Ak6kbc/3-biggest-risks-facing-workday-inc-cm814119,To anyone who has read my prior work my fondness for Workday Inc NYSE WDAY is no secret As noted elsewhere I believe the company is still in the early innings of its growth Despite my affinity for the cloud provider it isn t without its risks Workday stock is prone
HCM,HCM:UW,BBG00B6VCH45,Chi-Med to Announce 2017 Half-Year Financial Results,2017-06-29 09:20:00 +0000,https://finance.yahoo.com/news/chi-med-announce-2017-half-092000202.html?.tsrc=rss,"Hutchison China MediTech Limited will be announcing its interim results for the six months ended June 30, 2017 on Monday, July 31, 2017 at 7:00 am British Summer Time ."
HCM,HCM:UW,BBG00B6VCH45,"Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma",2017-06-29 07:44:00 +0000,https://finance.yahoo.com/news/chi-med-astrazeneca-initiate-savoir-074400754.html?.tsrc=rss,"Hutchison China MediTech Limited and AstraZeneca PLC today announce that they have initiated a global pivotal Phase III, open-label, randomized multi-center registration study of the highly selective inhibitor of c-MET receptor tyrosine kinase, savolitinib, in c-MET-driven papillary renal cell carcinoma ."
HCM,HCM:UW,BBG00B6VCH45,"It Sounds Crazy, But Workday Is Cheap",2017-06-27 13:52:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/593R-1SrJ18/it-sounds-crazy-but-workday-is-cheap-cm808509,Like many investors my early days of finding stocks were in the mold of Warren Buffett find companies that are trading at a discount to its intrinsic value These companies were typically popular brand names highly profitable and going through a funk It s a sound strategy
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL-453 in China,2017-06-22 06:30:00 +0000,https://finance.yahoo.com/news/chi-med-initiates-phase-ii-063000411.html?.tsrc=rss,"Hutchison China MediTech Limited has just initiated a Phase I/II clinical trial of HMPL-453 in China. HMPL-453 is a novel, highly selective and potent small molecule inhibitor targeting fibroblast growth factor receptor ."
HCM,HCM:UW,BBG00B6VCH45,Edison Issues ADR Update on Hutchison China MediTech (HCM),2017-06-13 15:20:00 +0000,https://finance.yahoo.com/news/edison-issues-adr-hutchison-china-152000001.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / June 13, 2017 / At ASCO, Hutchison China MediTech (NASDAQ: HCM) presented detailed Phase III trial results for one of its leading assets, fruquintinib (third-line colorectal cancer). ..."
HCM,HCM:UW,BBG00B6VCH45,Edison Issues Update on Hutchison China MediTech (HCM),2017-06-13 13:00:00 +0000,https://finance.yahoo.com/news/edison-issues-hutchison-china-meditech-130000182.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / June 13, 2017 / At ASCO, Hutchison China MediTech (NASDAQ: HCM) presented detailed Phase III trial results for one of its leading assets, fruquintinib (third-line colorectal cancer). ..."
HCM,HCM:UW,BBG00B6VCH45,Chi-Med steps closer to Chinese pharma first with drug filing,2017-06-13 08:20:03 +0000,https://finance.yahoo.com/news/chi-med-steps-closer-chinese-082003708.html?.tsrc=rss,"Hutchison China MediTech  , the Shanghai-based drugmaker listed in London, is a  step closer to winning approval for a modern drug developed in a  Chinese lab with the submission of its cancer medicine  fruquintinib to China's drug watchdog.  The company, controlled by Li Ka-shing's CK Hutchison  group, said on Monday the China Food and Drug  Administration would now review the drug as a treatment for  advanced colorectal cancer.  The move triggers a milestone payment of $4.5 million from  U.S. partner Eli Lilly to the Chinese firm, which is  commonly known as Chi-Med."
HCM,HCM:UW,BBG00B6VCH45,Chi-Med steps closer to Chinese pharma first with drug filing,2017-06-12 07:28:31 +0000,https://finance.yahoo.com/news/chi-med-steps-closer-chinese-072831147.html?.tsrc=rss,"Hutchison China MediTech  , the Shanghai-based drugmaker listed in London, is a  step closer to winning approval for a modern drug developed in a  Chinese lab with the submission of its cancer medicine  fruquintinib to China's drug watchdog.  The company, controlled by Li Ka-shing's CK Hutchison  group, said on Monday the China Food and Drug  Administration would now review the drug as a treatment for  advanced colorectal cancer.  The move triggers a milestone payment of $4.5 million from  U.S. partner Eli Lilly to the Chinese firm, which is  commonly known as Chi-Med."
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Submits New Drug Application to CFDA for Fruquintinib in Advanced Colorectal Cancer,2017-06-12 06:14:00 +0000,https://finance.yahoo.com/news/chi-med-submits-drug-application-061400783.html?.tsrc=rss,"Hutchison China MediTech Limited today announces that the China Food and Drug Administration has acknowledged acceptance of the New Drug Application for fruquintinib for the treatment of patients with advanced colorectal cancer, which triggers a milestone payment of RMB30.8 million from Lilly to Chi-Med."
HCM,HCM:UW,BBG00B6VCH45,InPlay from Briefing.com,2017-06-05 23:15:45 +0000,https://finance.yahoo.com/news/inplay-briefing-com-115750752.html?.tsrc=rss,InPlay from Briefing.com
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Highlights Phase III Fruquintinib Data in Oral Presentation at ASCO,2017-06-05 22:24:00 +0000,https://finance.yahoo.com/news/chi-med-highlights-phase-iii-222400021.html?.tsrc=rss,"Hutchison China MediTech Limited announced that results from its pivotal Phase III trial with fruquintinib, its novel vascular endothelial growth factor receptor kinase inhibitor, were highlighted in an oral presentation today during the American Society of Clinical Oncology Annual Meeting , held in Chicago."
HCM,HCM:UW,BBG00B6VCH45,Asian ADRs Move Higher in Tuesday Trading,2017-05-23 15:12:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9Xmag6QC0dY/asian-adrs-move-higher-in-tuesday-trading-cm793271,American depository receipts of Asian stocks were trading 0 23 higher at 158 02 on the Bank of New York Mellon Asia ADR Index on Tuesday American depository receipts of Asian stocks were trading 0 23 higher at 158 02 on the Bank of New York Mellon Asia ADR Index on Tuesday In North Asia
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Presents Clinical Data at ASCO 2017 Annual Meeting,2017-05-18 06:19:00 +0000,https://finance.yahoo.com/news/chi-med-presents-clinical-data-061900148.html?.tsrc=rss,"Hutchison China MediTech Limited today announces that new clinical data on three of its novel tyrosine kinase inhibitors, fruquintinib, savolitinib and sulfatinib, will be presented at the 2017 American Society of Clinical Oncology Annual Meeting, to be held in Chicago, Illinois from June 2 to 6, 2017."
HCM,HCM:UW,BBG00B6VCH45,Asian ADRs Move Higher in Monday Trading,2017-05-15 14:34:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S0cxrs17f8s/asian-adrs-move-higher-in-monday-trading-cm789174,American depository receipts of Asian stocks were trading 0 18 higher at 156 78 on the Bank of New York Mellon Asia ADR Index on Monday American depository receipts of Asian stocks were trading 0 18 higher at 156 78 on the Bank of New York Mellon Asia ADR Index on Monday In North Asia
HCM,HCM:UW,BBG00B6VCH45,Microsoft Announces First Official LinkedIn Integrations,2017-04-24 22:04:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3JKMynopMJ8/microsoft-announces-first-official-linkedin-integrations-cm778266,This is what salesforce com NYSE CRM was afraid of Just months after Microsoft NASDAQ MSFT closed its acquisition of professional networker LinkedIn with the final purchase price coming in right around 27 billion the software giant has now announced that it will
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Presented Pre-clinical Data for Fruquintinib and Sulfatinib at the American Association for Cancer Research Annual Meeting 2017,2017-04-07 06:19:00 +0000,http://finance.yahoo.com/news/chi-med-presented-pre-clinical-061900563.html?.tsrc=rss,"Hutchison China MediTech Limited presented pre-clinical data for fruquintinib and sulfatinib at the American Association for Cancer Research Annual Meeting 2017, held in Washington, D.C., USA from April 1 to 5, 2017."
HCM,HCM:UW,BBG00B6VCH45,"Chi-Med appoints Dr Weiguo Su, Chief Scientific Officer, to Board of Directors",2017-03-24 07:30:00 +0000,http://uk.finance.yahoo.com/news/chi-med-appoints-dr-weiguo-073000116.html,"Chi-Med appoints Dr Weiguo Su, Chief Scientific Officer, to Board of Directors"
HCM,HCM:UW,BBG00B6VCH45,"Chi-Med appoints Dr Weiguo Su, Chief Scientific Officer, to Board of Directors",2017-03-24 07:30:00 +0000,http://finance.yahoo.com/news/chi-med-appoints-dr-weiguo-073000896.html?.tsrc=rss,"Hutchison China MediTech Limited today announces that Dr Weiguo Su has been appointed as Executive Director and member of Technical Committee with effect from March 27, 2017."
HCM,HCM:UW,BBG00B6VCH45,Asian ADRs Edge Lower as Utility Stocks See Mixed Fortunes,2017-03-22 16:07:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WDG2DyPnCOY/asian-adrs-edge-lower-as-utility-stocks-see-mixed-fortunes-cm764144,American depository receipts of Asian stocks were 0 04 lower at 152 61 on the Bank of New York Mellon Asia ADR Index on Wednesday morning American depository receipts of Asian stocks were 0 04 lower at 152 61 on the Bank of New York Mellon Asia ADR Index on Wednesday morning Decliners in
HCM,HCM:UW,BBG00B6VCH45,"Chi-Med To Host R&D Briefings on March 29 & 30, 2017",2017-03-21 11:06:00 +0000,http://finance.yahoo.com/news/chi-med-host-r-d-110600751.html,[Business Wire] - Hutchison China MediTech Limited today announces that it will host Research & Development briefings in London and New York to provide an overview of the Company’s clinical pipeline of eight novel drug candidates.
HCM,HCM:UW,BBG00B6VCH45,"Chi-Med To Host R&D Briefings on March 29 & 30, 2017",2017-03-21 11:06:00 +0000,http://finance.yahoo.com/news/chi-med-host-r-d-110600751.html?.tsrc=rss,Hutchison China MediTech Limited today announces that it will host Research & Development briefings in London and New York to provide an overview of the Company’s clinical pipeline of eight novel drug candidates.
HCM,HCM:UW,BBG00B6VCH45,"Chi-Med To Host R&D Briefings on March 29 & 30, 2017",2017-03-21 11:06:00 +0000,http://uk.finance.yahoo.com/news/chi-med-host-r-d-110600465.html,"Chi-Med To Host R&D Briefings on March 29 & 30, 2017"
HCM,HCM:UW,BBG00B6VCH45,"Hutchison China MediTech Ltd. :HCM-US: Earnings Analysis: For the six months ended December 31, 2016 : March 17, 2017",2017-03-17 13:40:08 +0000,http://finance.yahoo.com/r/1f322ec5-78d1-3ffc-bafe-f1db5f655e69/hutchison-china-meditech-ltd-hcm-us-earnings-analysis-for-the-six-months-ended-december-31-2016-march-17-2017?yptr=yahoo&.tsrc=rss,"Categories:   Yahoo Finance Get free summary analysis Hutchison China MediTech Ltd. reports financial results for the half-year ended December 31, 2016. We analyze the earnings along side the following peers of Hutchison China MediTech Ltd. – OncoMed Pharmaceuticals, Inc. (OMED-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 109.48 million, Net Earnings of ... Read more    
<b>(Read more...)</b>"
HCM,HCM:UW,BBG00B6VCH45,"Hutchison China MediTech Ltd. :HCM-US: Earnings Analysis: For the six months ended December 31, 2016 : March 17, 2017",2017-03-17 13:40:08 +0000,http://www.capitalcube.com/blog/index.php/hutchison-china-meditech-ltd-hcm-us-earnings-analysis-for-the-six-months-ended-december-31-2016-march-17-2017/,"Hutchison China MediTech Ltd. :HCM-US: Earnings Analysis: For the six months ended December 31, 2016 : March 17, 2017"
HCM,HCM:UW,BBG00B6VCH45,HUTCHISON CHINA MEDITECH LTD Financials,2017-03-16 17:04:14 +0000,http://finance.yahoo.com/q/is?s=hcm,HUTCHISON CHINA MEDITECH LTD Financials
HCM,HCM:UW,BBG00B6VCH45,"International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 22nd and 23rd, 2017",2017-03-16 12:37:00 +0000,http://finance.yahoo.com/news/international-companies-host-live-webcasts-123700493.html,"[PR Newswire] - NEW YORK, March 16, 2017 /PRNewswire/ -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (""dbVIC"") on March 22 nd and 23 rd , featuring live webcast ..."
HCM,HCM:UW,BBG00B6VCH45,"International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 22nd and 23rd, 2017",2017-03-16 12:37:00 +0000,http://finance.yahoo.com/news/international-companies-host-live-webcasts-123700493.html?.tsrc=rss,"NEW YORK, March 16, 2017 /PRNewswire/ -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (""dbVIC"") on March 22 nd and 23 rd , featuring live webcast ..."
HCM,HCM:UW,BBG00B6VCH45,Chi-Med: Grant of Awards under Long Term Incentive Plan,2017-03-16 12:02:00 +0000,http://au.finance.yahoo.com/news/chi-med-grant-awards-under-120200414.html,"[Business Wire] - LONDON--(BUSINESSWIRE)-- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on March 15, 2017, it granted conditional awards (“LTIP Awards”) under the Long Term Incentive Plan ..."
HCM,HCM:UW,BBG00B6VCH45,Chi-Med: Grant of Awards under Long Term Incentive Plan,2017-03-16 12:02:00 +0000,http://finance.yahoo.com/news/chi-med-grant-awards-under-120200148.html?.tsrc=rss,"Hutchison China MediTech Limited announces that on March 15, 2017, it granted conditional awards under the Long Term Incentive Plan adopted by Chi-Med at its Annual General Meeting on April 24, 2015."
HCM,HCM:UW,BBG00B6VCH45,"Publication of Annual Report and Financial Results for the Year Ended December 31, 2016",2017-03-15 20:45:00 +0000,http://uk.finance.yahoo.com/news/publication-annual-report-financial-results-204500333.html,"Publication of Annual Report and Financial Results for the Year Ended December 31, 2016"
HCM,HCM:UW,BBG00B6VCH45,"Publication of Annual Report and Financial Results for the Year Ended December 31, 2016",2017-03-15 20:45:00 +0000,http://finance.yahoo.com/news/publication-annual-report-financial-results-204500943.html?.tsrc=rss,"Hutchison China MediTech Limited announced today that on Monday March 13, 2017, it filed its annual report on Form 20-F with the U.S."
HCM,HCM:UW,BBG00B6VCH45,Asian ADRs Move Higher in Monday Trading,2017-03-13 15:05:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/V7kMw5p-M7s/asian-adrs-move-higher-in-monday-trading-cm759950,American depository receipts of Asian stocks were trading 0 75 higher at 152 22 on the Bank of New York Mellon Asia ADR Index on Monday American depository receipts of Asian stocks were trading 0 75 higher at 152 22 on the Bank of New York Mellon Asia ADR Index on Monday In North Asia
HCM,HCM:UW,BBG00B6VCH45,3:54 am Hutchison China MediTech presents Phase Ib/II results for sulfatinib; shown to be well tolerated,2017-03-10 08:54:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#hcm,3:54 am Hutchison China MediTech presents Phase Ib/II results for sulfatinib; shown to be well tolerated
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Sulfatinib Phase Ib/II Results Presented at ENETS,2017-03-10 08:51:19 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-sulfatinib-085119698.html?.tsrc=rss,Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Sulfatinib Phase Ib/II Results Presented at ENETS,2017-03-10 08:51:19 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-sulfatinib-085119698.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of European Neuroendocrine Tumor Society,2017-03-10 07:39:00 +0000,http://finance.yahoo.com/news/chi-med-presented-sulfatinib-neuroendocrine-073900830.html?.tsrc=rss,"Hutchison China MediTech Limited presented data from the ongoing Phase Ib/II clinical trial of sulfatinib in patients with advanced neuroendocrine tumors at the 14th Annual Conference of European Neuroendocrine Tumor Society , held in Barcelona, Spain from March 8 to 10, 2017."
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of European Neuroendocrine Tumor Society,2017-03-10 07:39:00 +0000,http://uk.finance.yahoo.com/news/chi-med-presented-sulfatinib-neuroendocrine-073900173.html,Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of European Neuroendocrine Tumor Society
HCM,HCM:UW,BBG00B6VCH45,Asian ADRs Edge Higher in Friday Trading,2017-03-03 15:32:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n2g82paJ4ig/asian-adrs-edge-higher-in-friday-trading-cm755936,American depository receipts of Asian stocks were trading 0 03 higher at 151 24 on the Bank of New York Mellon Asia ADR Index on Friday American depository receipts of Asian stocks were trading 0 03 higher at 151 24 on the Bank of New York Mellon Asia ADR Index on Friday In North Asia
HCM,HCM:UW,BBG00B6VCH45,Billionaire Li's Biotech Firm a Step Closer to Putting New Cancer Drug on Market,2017-03-03 07:35:20 +0000,https://www.bloomberg.com/news/articles/2017-03-03/billionaire-li-s-biotech-moves-closer-to-new-drug-dream-in-china?cmpid=yhoo.headline,Billionaire Li's Biotech Firm a Step Closer to Putting New Cancer Drug on Market
HCM,HCM:UW,BBG00B6VCH45,Billionaire Li's Biotech Firm a Step Closer to Putting New Cancer Drug on Market,2017-03-03 07:35:20 +0000,http://finance.yahoo.com/r/bf706d10-aab3-3357-a7ae-add94f8ba590/billionaire-li-s-biotech-moves-closer-to-new-drug-dream-in-china?cmpid=yhoo.headline&yptr=yahoo&.tsrc=rss,"Hutchison China MediTech Ltd., the biotechnology company backed by billionaire Li Ka-shing, reported positive late-stage results for its drug to treat colorectal cancer, taking the company one step closer ..."
HCM,HCM:UW,BBG00B6VCH45,"Chi-Med Announces Positive Top-Line Results for FRESCO, its Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer",2017-03-03 07:31:00 +0000,http://uk.finance.yahoo.com/news/chi-med-announces-positive-top-073100459.html,"Chi-Med Announces Positive Top-Line Results for FRESCO, its Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer"
HCM,HCM:UW,BBG00B6VCH45,"Chi-Med Announces Positive Top-Line Results for FRESCO, its Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer",2017-03-03 07:31:00 +0000,http://finance.yahoo.com/news/chi-med-announces-positive-top-073100727.html?.tsrc=rss,"Hutchison China MediTech Limited today announces top-line results from FRESCO, its Phase III pivotal registration trial of fruquintinib in 416 patients with locally advanced or metastatic colorectal cancer in China, who failed at least two prior chemotherapies, including fluoropyrimidine, oxaliplatin and irinotecan."
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Positive Fruquintinib Pivotal Phase III Results,2017-03-03 07:27:28 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-positive-072728032.html?.tsrc=rss,Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Positive Fruquintinib Pivotal Phase III Results,2017-03-03 07:27:28 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-positive-072728032.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Asian ADRs Move Lower in Thursday Trading,2017-03-02 15:52:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TySxvAQ6Qtg/asian-adrs-move-lower-in-thursday-trading-cm755431,American depository receipts of Asian stocks were trading 0 63 lower at 152 10 on the Bank of New York Mellon Asia ADR Index on Thursday American depository receipts of Asian stocks were trading 0 63 lower at 152 10 on the Bank of New York Mellon Asia ADR Index on Thursday In North Asia
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Change of Directors,2017-02-28 12:42:29 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-change-124229683.html?.tsrc=rss,Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Change of Directors,2017-02-28 12:42:29 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-change-124229683.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Chi Med Appoints Graeme Jack as Independent Non-executive Director and Chairman of Audit Committee,2017-02-28 11:00:00 +0000,http://finance.yahoo.com/news/chi-med-appoints-graeme-jack-110000277.html?.tsrc=rss,"Hutchison China MediTech Limited today announces that with effect from March 1, 2017:-"
HCM,HCM:UW,BBG00B6VCH45,Chi Med Appoints Graeme Jack as Independent Non-executive Director and Chairman of Audit Committee,2017-02-28 11:00:00 +0000,http://uk.finance.yahoo.com/news/chi-med-appoints-graeme-jack-110000264.html,Chi Med Appoints Graeme Jack as Independent Non-executive Director and Chairman of Audit Committee
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma,2017-02-20 07:14:00 +0000,http://finance.yahoo.com/news/chi-med-initiates-phase-ii-071400088.html?.tsrc=rss,Hutchison China MediTech Limited today announces that a Phase II study of savolitinib has been initiated in locally advanced or metastatic pulmonary sarcomatoid carcinoma in China.
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma,2017-02-20 07:14:00 +0000,http://uk.finance.yahoo.com/news/chi-med-initiates-phase-ii-071400096.html,Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Start of Phase II Savolitinib PSC trial in China,2017-02-20 07:09:43 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-start-070943915.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Start of Phase II Savolitinib PSC trial in China,2017-02-20 07:09:43 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-start-070943915.html?.tsrc=rss,Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium,2017-02-14 10:16:00 +0000,http://finance.yahoo.com/news/chi-med-astrazeneca-present-savolitinib-101600496.html?.tsrc=rss,"Hutchison China MediTech Limited and AstraZeneca PLC will present data from the ongoing Phase II clinical trial of savolitinib in patients with papillary renal cell carcinoma at the 2017 Genitourinary Cancers Symposium sponsored by the American Society of Clinical Oncology , to be held in Orlando, Florida from February 16 to 18, 2017."
HCM,HCM:UW,BBG00B6VCH45,Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium,2017-02-14 10:16:00 +0000,http://au.finance.yahoo.com/news/chi-med-astrazeneca-present-savolitinib-101600622.html,[Business Wire] - LONDON--(BUSINESSWIRE)-- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) and AstraZeneca PLC (“AstraZeneca”) will present data from the ongoing Phase II clinical trial of savolitinib in ...
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR Inhibitor HMPL-453 in Australia,2017-02-14 07:44:00 +0000,http://uk.finance.yahoo.com/news/chi-med-initiates-first-human-074400537.html,Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR Inhibitor HMPL-453 in Australia
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR Inhibitor HMPL-453 in Australia,2017-02-14 07:44:00 +0000,http://finance.yahoo.com/news/chi-med-initiates-first-human-074400361.html?.tsrc=rss,"Hutchison China MediTech Limited today announces that it has initiated the first-in-human Phase I clinical trial of HMPL-453 in Australia. HMPL-453 is a novel, highly selective and potent small molecule inhibitor targeting fibroblast growth factor receptor ."
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Initiates Phase I of Novel FGFR Inhibitor HMPL-453,2017-02-14 07:42:08 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-initiates-074208916.html?.tsrc=rss,Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Initiates Phase I of Novel FGFR Inhibitor HMPL-453,2017-02-14 07:42:08 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-initiates-074208916.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Savolitinib PRCC Results Presentation at ASCO GU,2017-02-14 07:26:59 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-savolitinib-072659498.html?.tsrc=rss,Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Savolitinib PRCC Results Presentation at ASCO GU,2017-02-14 07:26:59 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-savolitinib-072659498.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Chi-Med to Announce 2016 Final Results,2017-02-06 07:00:00 +0000,http://finance.yahoo.com/news/chi-med-announce-2016-final-070000647.html,[Marketwired] - Hutchison China MediTech Limited
HCM,HCM:UW,BBG00B6VCH45,Chi-Med appoints Industry Veteran Karen Ferrante to Board of Directors,2017-02-01 12:06:00 +0000,http://uk.finance.yahoo.com/news/chi-med-appoints-industry-veteran-120600018.html,Chi-Med appoints Industry Veteran Karen Ferrante to Board of Directors
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Change of Directors,2017-02-01 07:18:21 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-change-071821274.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Asian ADRs Move Higher in Wednesday Trading,2017-01-25 15:50:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NaiBIjbXT5w/asian-adrs-move-higher-in-wednesday-trading-cm737984,American depository receipts of Asian stocks were trading 0 33 higher at 149 73 on the Bank of New York Mellon Asia ADR Index on Wednesday American depository receipts of Asian stocks were trading 0 33 higher at 149 73 on the Bank of New York Mellon Asia ADR Index on Wednesday In North Asia
HCM,HCM:UW,BBG00B6VCH45,Four High-Quality Stocks with 3% Dividend Yields,2017-01-23 19:30:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YLPKyStvLmA/four-high-quality-stocks-with-3-dividend-yields-cm736899,When Warren Buffett is looking for strong companies to invest in he employs both qualitative and quantitative tests to find the best candidates Durable competitive advantage and strong management are among the key qualitative measures and a go to quantitative metric in the Oracle s arsenal
HCM,HCM:UW,BBG00B6VCH45,Asian ADRs Edge Higher in Monday Trading,2017-01-23 15:50:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ucCmYge4Jho/asian-adrs-edge-higher-in-monday-trading-cm736671,American depository receipts of Asian stocks were trading 0 09 higher at 147 93 on the Bank of New York Mellon Asia ADR Index on Monday American depository receipts of Asian stocks were trading 0 09 higher at 147 93 on the Bank of New York Mellon Asia ADR Index on Monday In North Asia
HCM,HCM:UW,BBG00B6VCH45,Paycom Software Inc Has Room to Run,2017-01-20 02:36:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N5modJh0EIc/paycom-software-inc-has-room-to-run-cm735772,Paycom Software NYSE PAYC targets C suite executives and HR managers in the U S with its all in one human capital management HCM software solution a convenient alternative to cobbling together products from multiple vendors Instead of running one system to manage payroll
HCM,HCM:UW,BBG00B6VCH45,Oracle’s Strategy to Hit $10 Billion in SaaS Revenues,2017-01-16 16:36:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vnKHPe-Gmx8/oracles-strategy-to-hit-10-billion-in-saas-revenues-cm733935,Oracle ORCL was very late to the cloud party but the company has gotten aggressive with its strategy as it tries to beat Salesforce CRM to reach the 10 billion in annual sales mark with its Software as a Service SaaS products OracleOracle ORCL was very late to the
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Change of Directors,2017-01-16 11:29:00 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-change-112900596.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Chi-Med appoints Industry Veteran Paul Carter to Board of Directors,2017-01-16 11:23:00 +0000,http://uk.finance.yahoo.com/news/chi-med-appoints-industry-veteran-112300457.html,Chi-Med appoints Industry Veteran Paul Carter to Board of Directors
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Presents Phase I/II Clinical Data for Selective VEGFR Inhibitor Fruquintinib at the 2017 Gastrointestinal Cancers Symposium,2017-01-16 08:54:00 +0000,http://uk.finance.yahoo.com/news/chi-med-presents-phase-ii-085400045.html,Chi-Med Presents Phase I/II Clinical Data for Selective VEGFR Inhibitor Fruquintinib at the 2017 Gastrointestinal Cancers Symposium
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Initiates a Phase II Study of Sulfatinib in Second-line Biliary Tract Cancer in China,2017-01-16 08:52:00 +0000,http://uk.finance.yahoo.com/news/chi-med-initiates-phase-ii-085200098.html,Chi-Med Initiates a Phase II Study of Sulfatinib in Second-line Biliary Tract Cancer in China
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Initiates a Phase II Combination Study of Fruquintinib with Iressa® (gefitinib) in First-Line Non-Small Cell Lung Cancer,2017-01-16 08:47:00 +0000,http://au.finance.yahoo.com/news/chi-med-initiates-phase-ii-084700798.html,"[Business Wire] - LONDON--(BUSINESSWIRE)-- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated a Phase II study of a combination therapy using fruquintinib and Iressa® in the first-line setting for patients with advanced or metastatic non-small cell lung cancer (“NSCLC”) in China. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (“VEGFR”). This Phase II combination therapy study is a multi-center, single-arm, open-label study."
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Fruquintinib Phase I/II Clinical Data at ASCO GI,2017-01-16 08:45:17 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-fruquintinib-084517270.html,Hutchison China Meditech Limited: Fruquintinib Phase I/II Clinical Data at ASCO GI
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Sulfatinib Phase II Study in 2nd Line BTC in China,2017-01-16 08:18:16 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-sulfatinib-081816392.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Fruquintinib Combination Study in 1st-Line NSCLC,2017-01-16 08:02:43 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-fruquintinib-080243610.html,Hutchison China Meditech Limited: Fruquintinib Combination Study in 1st-Line NSCLC
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China,2017-01-10 07:16:00 +0000,http://uk.finance.yahoo.com/news/chi-med-initiates-hmpl-523-071600417.html,Chi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China
HCM,HCM:UW,BBG00B6VCH45,Total Voting Rights,2016-12-30 09:22:16 +0000,http://www.publicnow.com/view/44B2B4915B5211149E9EE392D1D28BE729602057,[at noodls] - Total Voting Rights The text version of this document is not available at the moment. The original content was posted at original link . Hutchison China Meditech Limited published this content on 30 December ...
HCM,HCM:UW,BBG00B6VCH45,Blocklisting Six Monthly Return,2016-12-29 09:12:12 +0000,http://www.publicnow.com/view/0D3529F46BDA9915139090E93715647E3DFB08CB,"[at noodls] - London: Thursday, December 29, 2016: Hutchison China MediTech Limited ('Chi-Med') (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech ..."
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Blocklisting Six Monthly Return,2016-12-29 08:22:41 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-blocklisting-082241640.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Director’s Share Dealing,2016-12-20 08:22:17 +0000,http://www.publicnow.com/view/8B9607D4A0093B639F914E8A01781ED982E43F05,[at noodls] - Director’s Share Dealing The text version of this document is not available at the moment. The original content was posted at original link . Hutchison China Meditech Limited published this content on ...
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Director's Share Dealing,2016-12-20 08:13:07 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-directors-081307811.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Is Marin Software Inc (MRIN) Going to Burn These Hedge Funds?,2016-12-14 14:34:27 +0000,http://www.insidermonkey.com/blog/is-marin-software-inc-mrin-going-to-burn-these-hedge-funds-509191/,Is Marin Software Inc (MRIN) Going to Burn These Hedge Funds?
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Director's Share Dealing,2016-12-14 08:05:43 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-directors-080543727.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Edison Issues ADR Update on Hutchison China MediTech (HCM),2016-12-12 15:31:00 +0000,http://finance.yahoo.com/news/edison-issues-adr-hutchison-china-153100036.html,"[Accesswire] - LONDON, UK / ACCESSWIRE / December 12, 2016 / At the recent IASLC World Conference on Lung Cancer, HCM published positive proof of concept data in NSCLC on key assets fruquintinib and epitinib. Affirmative ..."
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: HMPL-523 Pre-clinical Data Presented at ASH,2016-12-06 07:43:42 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-hmpl-074342499.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting,2016-12-06 07:13:00 +0000,http://au.finance.yahoo.com/news/chi-med-presents-pre-clinical-071300642.html,"[Business Wire] - LONDON--(BUSINESSWIRE)-- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from a recent pre-clinical study, investigating the in vitro and in vivo anti-tumor activities ..."
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Exercise of Share Options,2016-11-30 08:44:06 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-exercise-084406710.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Total Voting Rights,2016-11-30 08:40:21 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-total-084021298.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Exercise of Share Options by a Person Discharging Managerial Responsibilities,2016-11-30 08:25:07 +0000,http://www.publicnow.com/view/109AEB9DAEFE1BFA73039E54BF5E61CC1080A931,"[at noodls] - London: Wednesday, November 30, 2016: Hutchison China MediTech Limited ('Chi-Med') (AIM/Nasdaq: HCM) has received notification that Dr Weiguo Su, Executive Vice President and Chief Scientific Officer (being ..."
HCM,HCM:UW,BBG00B6VCH45,Total Voting Rights,2016-11-30 08:25:06 +0000,http://www.publicnow.com/view/0598CF914B140C8B0F3AF9F7B755746C8EF1CB19,"[at noodls] - London: Wednesday, November 30, 2016: For information purposes, Hutchison China MediTech Limited ('Chi-Med') (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 2016, the issued share ..."
HCM,HCM:UW,BBG00B6VCH45,Chi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer (“WCLC”),2016-11-29 12:00:00 +0000,http://uk.finance.yahoo.com/news/chi-med-present-data-proof-120000563.html,Chi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer (“WCLC”)
HCM,HCM:UW,BBG00B6VCH45,Asian ADRs Move Higher in Monday Trading,2016-11-28 15:30:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o55YqxCNY8w/asian-adrs-move-higher-in-monday-trading-cm714479,American depository receipts of Asian stocks were trading 0 17 higher at 143 54 on the Bank of New York Mellon Asia ADR Index on Monday American depository receipts of Asian stocks were trading 0 17 higher at 143 54 on the Bank of New York Mellon Asia ADR Index on Monday In North Asia
HCM,HCM:UW,BBG00B6VCH45,Director’s Share Dealing,2016-11-23 08:21:08 +0000,http://www.publicnow.com/view/42058E52B76C215BDA4236FC64046BDF95D8AFD1,"[at noodls] - London: Tuesday, November 1, 2016: Hutchison China MediTech Limited ('Chi-Med') (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, sold 10,000 ordinary ..."
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Director's Share Dealing,2016-11-23 08:11:33 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-directors-081133296.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Information Disclosure,2016-11-22 09:23:12 +0000,http://www.publicnow.com/view/7639488E07229B453B9FA374E41E8AA913D6DC01,[at noodls] - Information Disclosure The text version of this document is not available at the moment. The original content was posted at original link . Ho Chi Minh City Securities Corporation published this content ...
HCM,HCM:UW,BBG00B6VCH45,Chi-Med webcast presentation now available for on-demand viewing: Deutsche Bank ADR Virtual Investor Conference,2016-11-21 13:30:00 +0000,http://finance.yahoo.com/news/chi-med-webcast-presentation-now-133000316.html,"[PR Newswire] - LONDON, Nov. 21, 2016 /PRNewswire/ -- Hutchison China MediTech Limited (""Chi-Med"") (AIM/Nasdaq: HCM) today announces that their November 16, 2016 presentation from Chief Executive Officer, Christian ..."
HCM,HCM:UW,BBG00B6VCH45,Chi-Med webcast presentation now available for on-demand viewing: Deutsche Bank ADR Virtual Investor Conference,2016-11-21 13:30:00 +0000,http://finance.yahoo.com/news/chi-med-webcast-presentation-now-133000766.html,[CNW Group] - Chi-Med webcast presentation now available for on-demand viewing: Deutsche Bank ADR Virtual Investor Conference
HCM,HCM:UW,BBG00B6VCH45,ACR 2016: Phase I Dose Escalating Study of HMPL-523 in Australian Male Healthy Subjects,2016-11-15 12:08:12 +0000,http://www.publicnow.com/view/A915793016B4477D326C9150DCB1928BF576C5B8,"[at noodls] - A Phase I, Randomized, Double Blind, Placebo-Controlled, Dose Escalating Study of the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of HMPL-523 in Australian ..."
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting,2016-11-14 10:09:00 +0000,http://uk.finance.yahoo.com/news/chi-med-presents-phase-clinical-100900328.html,Chi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting
HCM,HCM:UW,BBG00B6VCH45,Deutsche Bank ADR Virtual Investor Conference (dbVIC),2016-11-14 02:17:04 +0000,http://www.publicnow.com/view/953F15521553C51B82A5C68BA5F09EB7CC6CAC59,[at noodls] - Deutsche Bank ADR Virtual Investor Conference (dbVIC) The text version of this document is not available at the moment. The original content was posted at original link . Hutchison China Meditech Limited ...
HCM,HCM:UW,BBG00B6VCH45,"Chi-Med to Present at the Deutsche Bank ADR Virtual Investor Conference on Wednesday, November 16, 2016",2016-11-10 13:30:00 +0000,http://finance.yahoo.com/news/chi-med-present-deutsche-bank-133000888.html,"[CNW Group] - Chi-Med to Present at the Deutsche Bank ADR Virtual Investor Conference on Wednesday, November 16, 2016"
HCM,HCM:UW,BBG00B6VCH45,"International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 16th and 17th, 2016",2016-11-10 13:00:00 +0000,http://finance.yahoo.com/news/international-companies-host-live-webcasts-130000518.html,"[CNW Group] - International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 16th and 17th, 2016"
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Director's Share Dealing,2016-11-01 16:59:07 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-directors-165907354.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Director's Share Dealing,2016-11-01 15:35:06 +0000,http://www.publicnow.com/view/40F1215BCD196152FBF77C0B8433F10270BF0014,[at noodls] - Director's Share Dealing The text version of this document is not available at the moment. The original content was posted at original link . Hutchison China Meditech Limited published this content on ...
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment,2016-10-31 07:00:00 +0000,http://uk.finance.yahoo.com/news/chi-med-commercial-platform-joint-070000249.html,Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment
HCM,HCM:UW,BBG00B6VCH45,Information Disclosure 29.2016: Financial Statement of Q3.2016,2016-10-20 12:19:08 +0000,http://www.publicnow.com/view/601E231F9EBADB35CFCCFDA156A19A4F4F9BC52A,[at noodls] - Information Disclosure 29.2016: Financial Statement of Q3.2016 The text version of this document is not available at the moment. The original content was posted at original link . Ho Chi Minh City Securities ...
HCM,HCM:UW,BBG00B6VCH45,Director's Share Dealing,2016-10-12 06:13:05 +0000,http://www.publicnow.com/view/371F7255E829A41850D0904D9E128851247963F1,"[at noodls] - London: Wednesday, October 12, 2016: Hutchison China MediTech Limited ('Chi-Med') (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, has sold 15,000 ..."
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Director's Share Dealing,2016-10-12 06:11:14 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-directors-061114657.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Information Disclosure 28.2016: Transaction of organization related to inside shareholder,2016-10-05 09:38:02 +0000,http://www.publicnow.com/view/A2C2693D56037F0D72690FAF6F4FC73A08627D4F,[at noodls] - Information Disclosure 28.2016: Transaction of organization related to inside shareholder The text version of this document is not available at the moment. The original content was posted at original link ...
HCM,HCM:UW,BBG00B6VCH45,Asian ADRs Move Lower in Monday Trading,2016-09-26 15:01:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0cEH1ZnVc-I/asian-adrs-move-lower-in-monday-trading-cm684492,American depository receipts of Asian stocks were trading 0 88 lower at 145 94 on the Bank of New York Mellon Asia ADR Index on Monday American depository receipts of Asian stocks were trading 0 88 lower at 145 94 on the Bank of New York Mellon Asia ADR Index on Monday In North Asia the
HCM,HCM:UW,BBG00B6VCH45,Information Disclosure 27.2016: Registration English - Disclosure of Information on HSX,2016-09-20 09:58:06 +0000,http://www.publicnow.com/view/2D22CBC77ABE457AFBEACCD5F5C2346FC38EF26D,[at noodls] - Information Disclosure 27.2016: Registration English - Disclosure of Information on HSX The text version of this document is not available at the moment. The original content was posted at original link ...
HCM,HCM:UW,BBG00B6VCH45,Information Disclosure 26.2016: Transaction of organization related to inside shareholder,2016-08-30 09:33:09 +0000,http://www.publicnow.com/view/D8B2C35C81C3E5832069642F06324B0A0CD79A7C,[at noodls] - Information Disclosure 26.2016: Transaction of organization related to inside shareholder The text version of this document is not available at the moment. The original content was posted at original link ...
HCM,HCM:UW,BBG00B6VCH45,"Hutchison China MediTech Ltd. :HCM-US: Earnings Analysis: For the six months ended June 30, 2016 : August 25, 2016",2016-08-25 13:33:10 +0000,http://www.capitalcube.com/blog/index.php/hutchison-china-meditech-ltd-hcm-us-earnings-analysis-for-the-six-months-ended-june-30-2016-august-25-2016/,"Hutchison China MediTech Ltd. :HCM-US: Earnings Analysis: For the six months ended June 30, 2016 : August 25, 2016"
HCM,HCM:UW,BBG00B6VCH45,Can Workday Clock Another Quarterly Beat?,2016-08-24 03:45:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eCNHrMdu6AU/can-workday-clock-another-quarterly-beat-cm669280,"Image source  Workday Inc.  Workday Inc. (NYSE  WDAY) is set to announce fiscal second quarter 2017 results this Wednesday, August 24, 2016, after the market close. With shares of the HR and"
HCM,HCM:UW,BBG00B6VCH45,"Chi-Med Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs",2016-08-17 02:51:01 +0000,http://www.publicnow.com/view/BFC22FCEE4D93E7B7C276F33CFCC69CB1ECAA87D,"[at noodls] - Group revenue up 27% to $104.5 million (H1 2015: $82.5m) and net income attributable to Chi‑Med of $0.5 million (H1 2015: $15.9m), reflecting a sharp increase in clinical investment. Innovation Platform ..."
HCM,HCM:UW,BBG00B6VCH45,Information Disclosure 25.2016: Notes of Business Result in H1.2016,2016-08-16 15:51:07 +0000,http://www.publicnow.com/view/C2878AEB21EBDFF929DDE35FBF6ABEDBC7A99945,[at noodls] - Information Disclosure 25.2016: Notes of Business Result in H1.2016 The text version of this document is not available at the moment. The original content was posted at original link . Ho Chi Minh City ...
HCM,HCM:UW,BBG00B6VCH45,Information Disclosure 23.2016: Financial Statement and Financial Safety Ratio Report of H1.2016,2016-08-15 15:01:03 +0000,http://www.publicnow.com/view/FE610F8E31811E01CC2BB9EE1A3D2405C7E7BC3D,[at noodls] - Information Disclosure 23.2016: Financial Statement and Financial Safety Ratio Report of H1.2016 The text version of this document is not available at the moment. The original content was posted at original ...
HCM,HCM:UW,BBG00B6VCH45,Information Disclosure 24.2016: Retreiving stocks of resigned employee in ESOP 2013 program,2016-08-15 07:51:04 +0000,http://www.publicnow.com/view/0C419CBEE9FE79F6F2142F093EA346200A06F2BA,[at noodls] - Information Disclosure 24.2016: Retreiving stocks of resigned employee in ESOP 2013 program The text version of this document is not available at the moment. The original content was posted at original ...
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Director's Share Dealing,2016-08-09 07:52:05 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-directors-075205076.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Director's Share Dealing,2016-08-09 07:30:08 +0000,http://www.publicnow.com/view/476175CC19B760CAB0F269974EA1C6199378C1ED,[at noodls] - Director's Share Dealing The text version of this document is not available at the moment. The original content was posted at original link . Hutchison China Meditech Limited published this content on ...
HCM,HCM:UW,BBG00B6VCH45,"Hutchison China MediTech Ltd. :HCM-GB: Earnings Analysis: For the six months ended June 30, 2016 : August 8, 2016",2016-08-08 06:26:17 +0000,http://www.capitalcube.com/blog/index.php/hutchison-china-meditech-ltd-hcm-gb-earnings-analysis-for-the-six-months-ended-june-30-2016-august-8-2016/,"Hutchison China MediTech Ltd. :HCM-GB: Earnings Analysis: For the six months ended June 30, 2016 : August 8, 2016"
HCM,HCM:UW,BBG00B6VCH45,Chi-Med 2016 Interim Results,2016-08-02 08:25:02 +0000,http://finance.yahoo.com/news/chi-med-2016-interim-results-082502674.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Change of Non-Executive Directors,2016-08-02 07:48:33 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-change-074833321.html,[Marketwired] - Hutchison China Meditech Limited
HCM,HCM:UW,BBG00B6VCH45,Hutchison China MediTech Limited (“Chi-Med”): Change of Non-executive Directors,2016-08-02 07:40:00 +0000,http://au.finance.yahoo.com/news/hutchison-china-meditech-limited-chi-074000782.html,"[Business Wire] - LONDON--(BUSINESSWIRE)-- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med ..."
HCM,HCM:UW,BBG00B6VCH45,Hutchison China MediTech Limited (“Chi-Med”): Change of Non-executive Directors,2016-08-02 07:40:00 +0000,http://uk.finance.yahoo.com/news/hutchison-china-meditech-limited-chi-074000388.html,Hutchison China MediTech Limited (“Chi-Med”): Change of Non-executive Directors
HCM,HCM:UW,BBG00B6VCH45,Change of Non-executive Directors,2016-08-02 07:31:05 +0000,http://www.publicnow.com/view/D7E165FD720E18426B4B03D90F8E2012DB6C4C42,"[at noodls] - London: Tuesday, August 2, 2016: Hutchison China MediTech Limited ('Chi-Med') (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director ..."
HCM,HCM:UW,BBG00B6VCH45,2016 Half-Year Financial Results,2016-08-02 06:51:01 +0000,http://www.publicnow.com/view/3266E4A15AC3E6A6A1478664D48DC4A4DAEBA352,[at noodls] - 2016 Half-Year Financial Results The text version of this document is not available at the moment. The original content was posted at original link . Hutchison China Meditech Limited published this content ...
HCM,HCM:UW,BBG00B6VCH45,"Hutchison China MediTech Limited (“Chi-Med”) Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs",2016-08-02 06:51:00 +0000,http://uk.finance.yahoo.com/news/hutchison-china-meditech-limited-chi-065100957.html,"Hutchison China MediTech Limited (“Chi-Med”) Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs"
HCM,HCM:UW,BBG00B6VCH45,"Hutchison China MediTech Limited (“Chi-Med”) Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs",2016-08-02 06:51:00 +0000,http://au.finance.yahoo.com/news/hutchison-china-meditech-limited-chi-065100410.html,"[Business Wire] - LONDON--(BUSINESSWIRE)-- Chi-Med (AIM/NASDAQ: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the global ..."
HCM,HCM:UW,BBG00B6VCH45,Chi-Med and AstraZeneca Amend Co-development Agreement to Accelerate Savolitinib Global Development Program,2016-08-01 07:32:00 +0000,http://uk.finance.yahoo.com/news/chi-med-astrazeneca-amend-co-073200539.html,Chi-Med and AstraZeneca Amend Co-development Agreement to Accelerate Savolitinib Global Development Program
HCM,HCM:UW,BBG00B6VCH45,Information Disclosure 22 .2016: Corporate Governance Statement H1.2016,2016-07-25 08:38:03 +0000,http://www.publicnow.com/view/AA69FF9D0C121E1EF3073B6A178E674A144E085B,[at noodls] - Information Disclosure 22 .2016: Corporate Governance Statement H1.2016 The text version of this document is not available at the moment. The original content was posted at original link . Ho Chi Minh ...
HCM,HCM:UW,BBG00B6VCH45,Bigger and better: 2016 IPOs that raised more than $100 million are up over 30%,2016-07-22 23:07:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/P4CrUASXu84/bigger-and-better-2016-ipos-that-raised-more-than-100-million-are-up-over-30-cm653642,"The 21 IPOs this year that have raised raised over $100 million have delivered investors an average return of 32%, including a first day pop of 14% and an additional 14% in the aftermarket. Most notably, only one IPO"
HCM,HCM:UW,BBG00B6VCH45,Cardiovascular Systems Seeks Device Approval in Japan,2016-07-07 14:45:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1qusXWXNEc4/cardiovascular-systems-seeks-device-approval-in-japan-cm645710,"Medical device manufacturer Cardiovascular Systems, Inc.CSII recently announced the submission of its Diamondback 360 Coronary Orbital Atherectomy System (OAS) Micro Crown for marketing approval at the Japan's Pharmaceuticals and Medical Devices Agency (PMDA). The company expects to commence the"
HCM,HCM:UW,BBG00B6VCH45,Chi-Med to Announce 2016 Half-Year Financial Results,2016-07-05 06:51:06 +0000,http://www.publicnow.com/view/A4D88EF066EA727CE75A226A4480B619BD7B302A,"[at noodls] - London: Tuesday, July 5, 2016: Hutchison China MediTech Limited ('Chi-Med') (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2016 on Tuesday, August 2, 2016 at ..."
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Chi-Med to Announce 2016 HY Financial Results,2016-07-05 06:00:00 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-chi-060000491.html,Hutchison China Meditech Limited: Chi-Med to Announce 2016 HY Financial Results
HCM,HCM:UW,BBG00B6VCH45,Blocklisting Six Monthly Return,2016-06-29 06:51:02 +0000,http://www.publicnow.com/view/76EB77B92BA70495B32F68E302BAEFB958A35BC0,[at noodls] - Blocklisting Six Monthly Return The text version of this document is not available at the moment. The original content was posted at original link . Hutchison China Meditech Limited published this content ...
HCM,HCM:UW,BBG00B6VCH45,Information Disclosure 20.2016,2016-06-28 08:41:01 +0000,http://www.publicnow.com/view/78154E67234C92E33C3B04295BB1CBC5FA474947,[at noodls] - Information Disclosure 20.2016 The text version of this document is not available at the moment. The original content was posted at original link . Ho Chi Minh City Securities Corporation published this ...
HCM,HCM:UW,BBG00B6VCH45,Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer,2016-06-20 12:21:00 +0000,http://uk.finance.yahoo.com/news/savolitinib-global-phase-ii-trial-122100202.html,Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Limited: Savolitinib Global Phase II Trial Initiated,2016-06-20 06:35:44 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-savolitinib-063544309.html,Hutchison China Meditech Limited: Savolitinib Global Phase II Trial Initiated
HCM,HCM:UW,BBG00B6VCH45,Block Admission,2016-06-15 07:29:09 +0000,http://www.publicnow.com/view/A2D3675FAA229266A7791839AEFC49EE8CB7E2B1,"[at noodls] - London: Wednesday, June 15, 2016: Hutchison China MediTech Limited ('Chi-Med') (AIM/Nasdaq: HCM) today announces that an application has been made to the London Stock Exchange plc for a block admission ..."
HCM,HCM:UW,BBG00B6VCH45,Hutchison China MediTech webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference,2016-06-13 12:30:00 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-webcast-presentation-123000007.html,Hutchison China MediTech webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference
HCM,HCM:UW,BBG00B6VCH45,International companies to host live webcasts at Deutsche Bank's June 9th and 10th Depositary Receipts Virtual Investor Conference,2016-06-06 13:00:00 +0000,http://finance.yahoo.com/news/international-companies-host-live-webcasts-130000840.html,"[PR Newswire] - NEW YORK, June 6, 2016 /PRNewswire/ -- Deutsche Bank today announced the lineup for its June 9 th and 10 th Depositary Receipts Virtual Investor Conference (""dbVIC""), featuring live webcast presentations ..."
HCM,HCM:UW,BBG00B6VCH45,"Hutchison China MediTech to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on June 10, 2016",2016-06-06 12:30:00 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-present-dbvic-123000694.html,"[PR Newswire] - Company invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event HONG KONG, June 6, 2016 /PRNewswire/ -- Hutchison China MediTech (LONDON STOCK ..."
HCM,HCM:UW,BBG00B6VCH45,Asian ADRs Move Lower in Wednesday Trading,2016-06-01 15:22:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LhHiWn36Ba8/asian-adrs-move-lower-in-wednesday-trading-cm628978,"American depository receipts of Asian stocks were trading 0.58% lower at 131.58 on the Bank of New York Mellon Asia ADR Index on Wednesday. In North Asia, the gainers are led by mobile enterprise solutions provider Kingtone Wirelessinfo Solution"
HCM,HCM:UW,BBG00B6VCH45,Total Voting Rights,2016-05-31 06:42:08 +0000,http://www.publicnow.com/view/E9C451AF0E1C7625D50EEE0B81C055AE4AC3C273,"[at noodls] - London: Tuesday, May 31, 2016: For information purposes, Hutchison China MediTech Limited ('Chi-Med') (AIM/Nasdaq: HCM) hereby notifies the market that as at May 31, 2016, the issued share capital of Chi-Med ..."
HCM,HCM:UW,BBG00B6VCH45,"What to Expect When Workday, Inc. Reports Earnings",2016-05-28 02:04:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nIdnWdA51sA/what-to-expect-when-workday-inc-reports-earnings-cm627809,"Image source  Workday Inc.  Workday Inc. (NYSE  WDAY) is set to release fiscal first quarter 2017 results Tuesday, May 31, 2016 after the market close. With shares of the HR and finance"
HCM,HCM:UW,BBG00B6VCH45,AACR 2016: Activity of Savolitinib against MET Ex14 mutations and resistance to METi through decoupling from MYC expression,2016-05-16 04:12:04 +0000,http://www.publicnow.com/view/7BE9F629C2DCAA95F9BE4B9952BAB0E9DBE0E964,"[at noodls] - Abstract (please download the poster for full details) Authors: Evan Barry, Ryan Henry, Alexandra Borodovsky, Elizabeth Maloney, Brendon Ladd, Melanie Frigault, Michael Zinda, Edwin Clark, Alwin Schuller ..."
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in Colorectal Cancer,2016-05-13 06:38:05 +0000,http://www.publicnow.com/view/65C2119E6DE63D0BB054AD8A6DD4C79FD4F51867,"[at noodls] - London: Friday, May 13, 2016: Hutchison China MediTech Limited ('Chi-Med') (AIM/Nasdaq: HCM) today announces that it has completed patient enrollment of FRESCO, its Phase III pivotal trial of fruquintinib ..."
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in Colorectal Cancer,2016-05-13 06:00:00 +0000,http://uk.finance.yahoo.com/news/chi-med-completes-enrollment-416-060000302.html,Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in Colorectal Cancer
HCM,HCM:UW,BBG00B6VCH45,Chi-Med to Participate in Two Healthcare Investor Conferences in May,2016-05-03 11:00:00 +0000,http://uk.finance.yahoo.com/news/chi-med-participate-two-healthcare-110000381.html,Chi-Med to Participate in Two Healthcare Investor Conferences in May
HCM,HCM:UW,BBG00B6VCH45,Hutchison China Meditech Becomes Oversold (HCM),2016-05-02 17:44:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iK0o9Q4UMNc/hutchison-china-meditech-becomes-oversold-hcm-cm614737,"Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis"
HCM,HCM:UW,BBG00B6VCH45,Don't Be Deceived by Workday Inc.'s Lack of Profitability,2016-04-28 23:08:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L3EkbWswonA/dont-be-deceived-by-workday-incs-lack-of-profitability-cm613526,"Over the past five years, net income at cloud software provider Workday has decreased from negative $80 million to negative $290 million. Yet, since its IPO in October 2012, the stock price has"
HCM,HCM:UW,BBG00B6VCH45,Hutchison China MediTech Limited Announces Exercise of Overallotment Option,2016-04-13 15:55:00 +0000,http://uk.finance.yahoo.com/news/hutchison-china-meditech-limited-announces-155500652.html,Hutchison China MediTech Limited Announces Exercise of Overallotment Option
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Initiates First-in-Human Clinical Trial of Novel PI3K Inhibitor HMPL-689,2016-04-12 06:00:00 +0000,http://uk.finance.yahoo.com/news/chi-med-initiates-first-human-060000797.html,Chi-Med Initiates First-in-Human Clinical Trial of Novel PI3K Inhibitor HMPL-689
HCM,HCM:UW,BBG00B6VCH45,"Hutchison China MediTech Limited (HCM), Interview with Christian Hogg, Executive Director and CEO",2016-04-07 16:38:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ciLhKTuhQWQ/hutchison-china-meditech-limited-hcm-interview-withchristian-hoggexecutive-director-andceo-cm603190,"Watch the CEO Signature Series  interview with Christian Hogg, Executive Director and Chief Executive Officer  of Hutchison China MediTech Limited ( HCM ).     Christian Hogg, Executive Director and CEO     CEO Bio:   Mr Hogg joined Hutchison China in 2000 and has since led all aspects of the creation,"
HCM,HCM:UW,BBG00B6VCH45,Renaissance Capital's 1Q16 US IPO Market Review,2016-04-01 22:28:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nVgjwiVumJY/renaissance-capitals-1q16-us-ipo-market-review-cm598858,"The US IPO market in the 1Q16 hit its lowest levels since the depths of the financial crisis in 2008 2009. Not a single deal priced outside of the health care sector, where eight deals managed to raise $0.7"
HCM,HCM:UW,BBG00B6VCH45,Top-Rated Stock Picks and Most-Read Stories at Nasdaq.com: March 20 - 26,2016-03-29 15:04:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EjxIO2GU2Ec/top-rated-stock-picks-and-most-read-stories-at-nasdaqcom-march-20-26-cm598851,Welcome to the latest installment of community stock picks and overview of the most-read stories of the week. We're taking a look at stocks chosen by members of the Nasdaq.com community from March 20 - 26.   Bullish Stocks: Here’s What You Said:   Apple ( AAPL ): New Apple watch straps will likely increase sales.
HCM,HCM:UW,BBG00B6VCH45,Hutchison China MediTech Limited Announces Closing of U.S. Public Offering of ADSs Raising Approximately US$101 Million on the Nasdaq Stock Market,2016-03-22 14:30:00 +0000,http://uk.finance.yahoo.com/news/hutchison-china-meditech-limited-announces-143000408.html,Hutchison China MediTech Limited Announces Closing of U.S. Public Offering of ADSs Raising Approximately US$101 Million on the Nasdaq Stock Market
HCM,HCM:UW,BBG00B6VCH45,US IPO Weekly Recap: Two healthcare companies price amid an improving market backdrop,2016-03-21 21:09:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/g3gmhEn53Wo/us-ipo-weekly-recap-two-healthcare-companies-price-amid-an-improving-market-backdrop-cm595315,"Of the three scheduled healthcare offerings this past week, only two priced. This marks a total of seven IPOs year to date, all from healthcare companies, which have been predominantly development stage biotechs supported by existing backers.  While the broader market is"
HCM,HCM:UW,BBG00B6VCH45,Chi-Med Initiates Sulfatinib Phase III Registration Study in Pancreatic Neuroendocrine Tumor Patients,2016-03-21 11:34:00 +0000,http://uk.finance.yahoo.com/news/chi-med-initiates-sulfatinib-phase-113400769.html,Chi-Med Initiates Sulfatinib Phase III Registration Study in Pancreatic Neuroendocrine Tumor Patients
HCM,HCM:UW,BBG00B6VCH45,"Week Ahead: An empty IPO calendar, even as markets become more receptive",2016-03-21 03:14:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YAOrcGXzXww/week-ahead-an-empty-ipo-calendar-even-as-markets-become-more-receptive-cm588696,"No deals are on the calendar for the week ahead.KLR Energy Acquisition ( KLREU ), a blank check company led by the former CEO of EPL Oil & Gas, will attempt to raise $100 million in the week ahead."
HCM,HCM:UW,BBG00B6VCH45,2 Healthcare IPOs on Calendar for Holiday-Shortened Week,2016-03-20 13:14:51 +0000,http://247wallst.com/investing/2016/03/20/2-healthcare-ipos-on-calendar-holiday-shortened-week/,2 Healthcare IPOs on Calendar for Holiday-Shortened Week
HCM,HCM:UW,BBG00B6VCH45,Hutchison China MediTech Limited Announces Pricing of U.S. Public Offering of ADSs,2016-03-17 03:35:00 +0000,http://finance.yahoo.com/news/hutchison-china-meditech-limited-announces-033500111.html,"[Business Wire] - Hutchison China MediTech Limited announces the pricing of its U.S. public offering of American depositary shares , raising gross proceeds of approximately US$101.25 million."
HCM,HCM:UW,BBG00B6VCH45,Cancer therapies from China: Hutchison China MediTech prices $101 million US IPO at $13.50,2016-03-17 00:47:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uri3aynAzs0/cancer-therapies-from-china-hutchison-china-meditech-prices-101-million-us-ipo-at-1350-cm594243,"Hutchison China MediTech, a CK Hutchison backed pharmaceutical with a pipeline of oncology candidates, raised $101 million by offering 7.5 million ADSs at $13.50. In its most recent filing, the company expected to raise $100 million by offering 6.1"
HCM,HCM:UW,BBG00B6VCH45,Week ahead: IPO calendar fills up,2016-03-14 15:39:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uR5Zr6uA4wU/week-ahead-ipo-calendar-fills-up-cm592316,"After seeing just one IPO price in the past month, and five this year, there are three IPOs on the calendar next week.  The increased activity comes on the heels of IPO index outperformance. Since the February 11 lows, the"
HCM,HCM:UW,BBG00B6VCH45,Cancer drugs made in China: Hutchison China MediTech sets terms for $100 million US IPO,2016-03-05 00:36:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rxEK22NoI6E/cancer-drugs-made-in-china-hutchison-china-meditech-sets-terms-for-100-million-us-ipo-cm588703,"Hutchison China MediTech, a CK Hutchison backed pharmaceutical with a pipeline of immuno oncology candidates, announced terms for its IPO on Friday. The Hong Kong based company plans to raise $100 million by offering 6.1 million ADSs at a"
HCM,HCM:UW,BBG00B6VCH45,8 Oversold Stocks with Decreasing Shares Shorted,2011-03-31 18:20:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Baxss5kRKnA/8-oversold-stocks-with-decreasing-shares-shorted-cm69069,"Here we present 8 oversold stocks, with RSI(14) readings below 40. These stocks have also seen decreasing short interest month-over-month.  Do you think this bullish behavior is likely to continue for these names?   Analyze These Ideas (Tools Will Open In A New Window)      1. Access a  thorough description of all"
